GANX - Gain Therapeutics, Inc. Stock Price, Fair Value and News

$1.63+0.03 (+1.88%)

Delayed as of 27 Dec 2024, 11:24 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

GANX Price Action

Last 7 days

1.9%

Last 30 days

-7.5%

Last 90 days

-19.6%

Trailing 12 Months

-42.2%

GANX RSI Chart

GANX Valuation

Market Cap

42.4M

Price/Earnings (Trailing)

-1.99

Price/Sales (Trailing)

841.23

EV/EBITDA

-1.48

Price/Free Cashflow

-2.01

GANX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

GANX Fundamentals

GANX Revenue

Revenue (TTM)

55.2K

GANX Earnings

Earnings (TTM)

-21.4M

Earnings Growth (Yr)

4.93%

Earnings Growth (Qtr)

44.91%

GANX Profitability

EBT Margin

-38637.83%

Return on Equity

-239.83%

Return on Assets

-148.74%

Free Cashflow Yield

-49.67%

GANX Investor Care

Shares Dilution (1Y)

105.46%

Diluted EPS (TTM)

-1.1

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	150.3K	55.2K	55.2K	55.2K
2022	204.7K	210.7K	183.3K	140.1K
2021	27.5K	110.3K	130.9K	165.0K
2020	0	0	0	28.9K

Get all data in R, Python etc through our Historical Stock Data APIs

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc., a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. Its lead product candidate includes GT-02287, for the treatment of GBA1 Parkinson's disease. In addition, the company is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

CEO	Mr. Matthias Alder LIC. IUR., LL.M.
WEBSITE	gaintherapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	28

Gain Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Gain Therapeutics, Inc.? What does GANX stand for in stocks?

GANX is the stock ticker symbol of Gain Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Gain Therapeutics, Inc. (GANX)?

As of Thu Dec 26 2024, market cap of Gain Therapeutics, Inc. is 42.44 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GANX stock?

You can check GANX's fair value in chart for subscribers.

Is Gain Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether GANX is over valued or under valued. Whether Gain Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Gain Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GANX.

What is Gain Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Dec 26 2024, GANX's PE ratio (Price to Earnings) is -1.99 and Price to Sales (PS) ratio is 841.23. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GANX PE ratio will change depending on the future growth rate expectations of investors.